A5278

Pharmacology Substudies of A5263 and A5264

Sponsors:
US National Institute of Allergy and Infectious Diseases (NIAID)
The National Cancer Institute (NCI)
National Institute on Dental Craniofacial Research (NIDCR)

Protocol Summary:
A5278 is designed to assess the direction and magnitude of pharmacokinetic (PK) interactions between the antiretroviral agents efavirenz/tenofovir/emtricitabine (EFV/TDF/FTC) and the Karbosi’s sarcoma (KS) chemotherapy agents etoposide (ET), vincristine (VCR), and paclitaxel (PTX).

Years: 2013 – 2014

Investigator: Margaret Borok-Williams, MD, CHB, MMED

Location: Parirenyatwa CRS

ACTG

Completed Study

Publication:

Comments are closed.

Website by Canton Becker